AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ALMR · NASDAQ · Biotechnology

Alamar Biosciences

Supplies NULISA assays and ARGO HT automation for protein-biomarker measurement.

$30.71

After-hours close−0.02 (−0.07%)

At close$30.73(−6.88%)

Something off on this page? Send us feedback.

Profile

Alamar Biosciences, Inc.ALMRHealth Care

Sells automated precision-proteomics instruments, NULISA assays, consumables, and services to research and biopharma customers. Its model combines instrument placement with proprietary consumables and service activity.

Pairs NULISA assays with the automated ARGO HT benchtop system to measure protein biomarkers at very low concentrations in blood and other biological samples. The research-use-only platform serves research and academic institutions, biopharmaceutical companies, contract research organizations, and service laboratories.

The portfolio includes NULISAseq high-plex panels and NULISAqpcr single- or low-plex assays, with next-generation-sequencing or qPCR readouts for discovery and targeted applications. Its customer base extends internationally, and the business combines instrument placement, proprietary consumables, and services.

Commercial development depends on continued adoption of the ARGO/NULISA ecosystem by research and biopharma customers. The platform is designed for research use rather than clinical diagnostic use.

Company facts

CEOYuling Luo, Ph.D.

ListedApr 17, 2026

ExchangeNASDAQ

HeadquartersFremont, CA

CountryUnited States

Employees222

CIK0002104204

ISINUS0109111056

Key statistics

Market cap$2.13B

EPS (ttm)−$0.5885

P/E (ttm)−52.18

ROE-178.4%

P/B5.76

P/S38.38

Dividend yield—

Beta—

Year to date +39.7% · Average volume (30d) 307.0K

Analysts

Price target, next 12 months$33.50+9.1%Median of 2 analysts · vs the Aug 28 close

ConsensusBuy2 of 2 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $30.71

High$35.00+14.0%

Median$33.50+9.1%

Low$32.00+4.2%

4 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Prior target	Target
Aug 11, 2026	Stifel Nicolaus	Target	$28	$32
May 12, 2026	Leerink Partners	Target		$35
May 12, 2026	Stifel Nicolaus	Target		$28

Earnings

EPS

Estimate−$0.31

Reported−$0.22+28.5%

Revenue

Estimate$25.9M

Reported$29.4M+13.7%

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 10, 2026Q2 FY26	−$0.31	−$0.22	+28.5%	$25.9M	$29.4M	+13.7%	+30.65%
May 8, 2026Q1 FY26	−$1.71	−$1.74	−1.8%	$26.0M	$26.0M	+0.1%	−0.33%

View details

Financial highlights

	—	—	—	—	Q1 FY26	Q2 FY26
Revenue	—	—	—	—	$26.0M	$29.4M
Gross profit	—	—	—	—	$14.5M	$17.7M
Operating income	—	—	—	—	−$12.3M	−$13.5M
Net income	—	—	—	—	−$21.3M	−$13.2M
Diluted EPS	—	—	—	—	−$0.31	−$0.22
Gross margin	—	—	—	—	55.5%	60.2%
Operating margin	—	—	—	—	-47.4%	-46.0%

Revenue by product · Q2 FY26

Consumables$15.5M · 53%

Instruments$7.8M · 26%

Service$6.2M · 21%

Revenue by geography · Q2 FY26

United States$19.7M · 67%

EMEA$6.6M · 22%

Asia Pacific$2.7M · 9%

Americas$503.0K · 2%

Balance sheet, Jun 30, 2026Cash & short-term investments $250.1M · Total debt $51.4M · Total assets $391.0M · Shareholders' equity $312.9M

Dividends

No dividends on record.

Ownership

Institutions 35.34%24.49M sharesInsiders 8.77%6.08M sharesOther 55.89%38.74M shares

Shares outstanding 69.31M · Float 36.08M · 52.1% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Qiming Corporate GP VI, Ltd	7.07M	10.20%	13G	Aug 11, 2026
Nicholas Naclerio	6.36M	9.60%	13D	Apr 23, 2026
Yuling Luo	4.53M	6.40%	13G	Aug 13, 2026
Sands Capital Alternatives, LLC	4.23M	6.10%	13D	Jul 7, 2026
Sherpa Healthcare Fund Ii, L.P.	3.97M	5.70%	13G	Jul 2, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Apr 20, 2026	Nicholas Naclerio	director	+235,294	$17.00
Apr 20, 2026	Illumina Innovation Fund II GP, L.L.C.	10 percent owner	+235,294	$17.00